Pre-Market Earnings Report for February 4, 2026 : LLY, ABBV, UBER, UBS, BSX, CME, BAM, JCI, COR, PSX, YUM, CTSH

Major U.S. and international names are due to report Dec‑quarter results on 02/04/2026 with published consensus EPS showing mixed expectations: Eli Lilly $6.99 (+31.39% YoY), AbbVie $2.66 (+23.15%), Uber $0.79 (‑75.39%), UBS $0.25 (+8.70%), Boston Scientific $0.78 (+11.43%), CME $2.74 (+8.73%), Brookfield $0.42 (+5.00%), Phillips 66 $2.11 (+1506.67%), Yum! $1.78 (+10.56%) and Cognizant $1.32 (+9.09%). Several stocks trade at premium P/E multiples versus industry peers (e.g., LLY 43.98 vs industry 17.20; ABBV 22.68 vs 17.20), while past beats/misses are noted for guidance on analyst positioning. The results could re‑rate individual equities and influence sector allocation given the dispersion in expected earnings and valuation differentials.

Analysis

Market structure: Pharma (LLY, ABBV) and select cyclicals (PSX, JCI) are positioned as near-term winners if consensus EPS prints hold — LLY priced at ~44x 2025 EPS implies >10% downside if guidance disappoints, while ABBV’s consistent beats suggest 6–12% short-term re-rate potential. UBER’s forecasted 75% EPS decline is a clear loser for internet/consumer risk-on flows and suggests margin pressure in mobility/delivery; that weak print would pressure discretionary reopening trades and increase equity dispersion. Commodity link: PSX’s +1,507% YoY EPS swing signals a refining margin recovery; oil moves >$5/bbl intraday will materially shift PSX earnings sensitivity and crack spreads, and push corporate fuel-cycle correlated FX and CAD/NOK moves.

Risk assessment: Tail risks include FDA or drug-pricing rulings (Adverse rulings could knock 15–30% off high-P/E pharma), an OPEC surprise cutting output (oil +10%+ in 30 days, inflating PSX upside but pressuring consumer names), and European bank regulatory moves hitting UBS. Time horizons: expect volatility in days around releases, guidance-driven repricing over 4–12 weeks, and structural effects (pipeline, biosimilars for ABBV) realized over quarters. Hidden dependencies: ABBV’s margin resilience depends on Humira-family revenue trajectory and biosimilar uptake; CME volumes correlate nonlinearly with realized vol and Fed policy communication.

Trade implications: Direct: establish tactical 1.5–3% long in ABBV (target +8–15% in 3 months on another beat) and 1–2% long in CME for 3–6 months as fee growth stabilizer. Short: initiate a 1–2% short or buy 6–8 week ATM puts on UBER if EPS miss or guidance cut — implied move >20% is likely. Options: buy 8–30 day straddles on LLY only if implied vol < historical post-earnings move (take if IV discount >15% vs realized); for PSX, go long call spreads (2–4 month) conditional on Brent > $80 for two consecutive weeks.

Contrarian angles: The market may over-penalize LLY for P/E risk while underappreciating ABBV’s cash-flow resilience — consider relative-long ABBV vs short LLY if LLY guidance is conservative. UBER’s 75% EPS drop could be one-off accounting or investment-related; a large post-earnings selloff would present a 2–3 month mean-reversion trade if guidance stabilizes. Historical parallels: 2014–2016 pharma re-rates after single-drug failures show rapid >25% drawdowns, so hedge high-P/E pharma exposure with 3–6 month puts. Unintended consequence: aggressive positioning into PSX ahead of an oil inventory surprise could flip the trade within days; set tight triggers.

Key Decisions for Investors

• Establish a 2% portfolio long position in ABBV on approval-consistent guidance or beat — target +8–15% in 3 months; implement a 6% trailing stop-loss and reduce to 1% if guidance is tempered.
• Initiate a 1.5% short (or buy 6–8 week ATM puts) on UBER into the print if EPS misses or guidance is cut; add to 3% total if shares gap down >10% intraday and guidance remains weak.
• Add a 1.5–2% long in CME for 3–6 months as a volatility/flow play; trim by 50% if daily ADV in futures/option volumes falls >20% month-over-month or Fed signals sustained easing.
• Execute a conditional PSX trade: buy 3–6 month call spreads sized 1% if Brent crude closes above $80 for two consecutive trading days; stop-loss if Brent falls below $70 for five days.
• Hedge concentrated pharma exposure (LLY or others >3% position) with 3–6 month puts sized at 30–50% notional; unwind if biotech/FDA headlines are neutral for 10 consecutive trading days.